














































Increasing evidence suggests that the insulin-like 
growth factor-I (IGF-I)/insulin signalling pathway plays 
a pivotal role in the regulation of longevity [1-6]. In the 
Caenorhabditis elegans and in the Drosophila 
melanogaster it has been suggested that the down-
regulation of IGF-I/insulin signalling significantly 
extends survival [1, 2].  
 
 












































In humans, GH/IGF-I secretion and insulin sensitivity 
decline with aging [1, 2, 7] and insulin resistance is 
associated with increased morbidity and mortality [8]. 
Data on IGF-I system in relation to longevity are still 
controversial. Bonafè et al. [9] previously found that 
subjects with at least an A allele of the IGF-I receptor 
(IGF-IR) gene (G/A, codon 1013) had low levels of free 
plasma IGF-I and were more represented among long-
lived people. In contrast, Paolisso et al. [10] found an 

























Abstract: Centenarians'  offspring  represent  a  suitable  model  to  study  age‐dependent  variables  (e.g.  IGF‐I)  potentially
involved  in the modulation of the  lifespan. The aim of the present study was to  investigate the role of the  IGF‐I  in human
longevity. We evaluated circulating IGF‐I bioactivity measured by an innovative IGF‐I Kinase Receptor Activation (KIRA) Assay,
total IGF‐I, IGFBP‐3, total IGF‐II, insulin, glucose, HOMA2‐B% and HOMA2‐S% in 192 centenarians' offspring and 80 offspring‐
controls of which both parents died  relatively  young. Both  groups were well‐matched  for  age,  gender  and BMI with  the
centenarians'  offspring.  IGF‐I  bioactivity  (p<0.01),  total  IGF‐I  (p<0.01)  and  the  IGF‐I/IGFBP‐3  molar  ratio  (p<0.001)  were
significantly lower in centenarians' offspring compared to offspring matched‐controls. Serum insulin, glucose, HOMA2‐B% and
HOMA2‐S% values were similar between both groups. In centenarians' offspring IGF‐I bioactivity was inversely associated to
insulin  sensitivity.  In  conclusion:  1)  centenarians'  offspring  had  relatively  lower  circulating  IGF‐I  bioactivity  compared  to
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increased plasma IGF-I/IGF binding protein 3 (IGFBP-
3) molar ratio in healthy centenarians compared to aged 
subjects. They suggested that this elevated ratio 
reflected higher IGF-I bioavailability which contributed 
to the observed improved insulin action in centenarians. 
An overrepresentation of heterozygous mutations in the 
IGF-IR gene associated with high serum IGF-I levels 
and reduced activity of the IGF-IR has been reported in 
Ashkenazi Jewish centenarians compared to controls 
[11]. In addition, in humans positive associations 
between circulating total IGF-I levels and cancer 
mortality have been found in many studies [12-14], 
while low total IGF-I levels have been associated with 
an increased risk for cardiovascular diseases and 
diabetes [15-22]. On the other hand, Rozing et al. 
showed that offspring of familial nonagenarians 
displayed similar IGF-I and IGFBP-3 levels compared 
to their partners [23]. 
 
These conflicting results probably reflect the 
complexity of the IGF-system. We recently developed 
an IGF-I kinase receptor activation (KIRA) assay to 
assess circulating IGF bioactivity [24-27]. This assay 
determines IGF-I bioactivity by quantifying 
phosphorylation of tyrosine residues of the activated 
IGF-IR after stimulation with human serum in vitro. 





























KIRA assay is able to integrate the modifying effects of 
IGFBPs and proteases on the interaction between IGF-I 
and the IGF-IR. Thus by using the IGF-I KIRA it is 
possible to measure the overall IGF-IR activation in 
blood [24-27]. Recently it was also found that IGF-I 
bioactivity, as measured by the IGF-I KIRA, is lower in 
more insulin sensitive subjects [28], underlining the 
strict interaction between IGF-I and insulin pathways.  
To clarify the role of the IGF-I system in human 
lifespan, we investigated circulating IGF-I bioactivity  
and other parameters of the IGF/insulin system in 
centenarians' offspring and in a properly selected group 
of offspring matched-controls. Parameters of the 
IGF/insulin system were also studied in centenarians 




Health status in centenarians' offspring and 
offspring matched-controls  
 
Baseline characteristics of participants are shown in 
Table 1. Centenarians' offspring and offspring matched-
controls were comparable for age, gender, height, BMI, 
waist/hip ratio, systolic and diastolic blood pressures, 
serum total cholesterol and triglycerides levels and 








































Age (yrs) 71 (69-75) 71 (65-75) 100 (100-102) 0.66 <0.001 




26/80 (24.5/75.5) 0.92 0.03 
Height (cm) 162.1 ± 8.3 161.9 ± 9 150 ± 8.9 0.94 <0.001 
BMI (kg/m2) 27.3 (24.8-29.9) 26.1 (23.6-
28.7) 
23.6 (21.3-26.8) 0.09 <0.001 
Waist/Hip ratio 0.89 ± 0.08 0.87 ± 0.08 0.89 ± 0.08 0.56 0.17 
Systolic Blood Pressure 
(mm Hg) 
134 (120-145) 130 (121-
140) 
125 (120-140) 0.97 <0.01 
Diastolic Blood Pressure 
(mmHg) 
80 (72-85) 80 (70-82) 70 (60-78) 0.96 <0.001 
Total Cholesterol (mg/dL) 196 (172-218) 203 (174-
231) 
185 (163-213) 0.57 0.006 
HDL-Cholesterol (mg/dL) 56 (46-78) 50 (42-64) 47 (40-55) 0.06 0.01 
Triglycerides (mg/dL) 105 (79-148) 109 (83-150) 108 (82-143) 0.92 0.97 
Smoking at present: yes/no 
(%) 
13/66 (16.5/83.5) 23/162 
(12.4/87.6) 


































The prevalence of several age-related diseases (Table 2) 
was lower in centenarians' offspring than in offspring 
matched-controls. Differences in prevalence of 
hypertension (p<0.001) and arrhythmia (p=0.006) were 
significant between both groups, while differences in 
prevalence of cancer and osteoarthrosis were borderline 
significant (both p=0.06). In addition, the proportion of 
subjects using medications (p=0.001) and the number of 
prescribed drugs (p<0.001) were significantly lower in 
centenarians' offspring than in offspring matched-
controls (Table 2).  
 
IGF/insulin system in centenarians' offspring and 
offspring matched-controls 
 
Baseline levels of IGF-I system parameters are shown 
in Table 3. Circulating IGF-I bioactivity, evaluated by 
KIRA, and total IGF-I were significantly lower in 
centenarians' offspring than in offspring matched-
controls (both p<0.01). Serum IGFBP-3 (p=0.01) and 
total IGF-I/IGFBP-3 molar ratio (p<0.001) were 
respectively higher and lower in centenarians' offspring 
than in offspring matched-controls. Differences in IGF-I 
bioactivity, total IGF-I, IGFBP-3, total IGF-I/IGFBP-3 
molar ratio between both groups remained significant 
after correction for age, gender and BMI (p=0.001, 
p<0.01, p<0.01 and p<0.001, respectively). No 




























se, insulin, HOMA2-B% and HOMA2-S% were 
observed between centenarians' offspring and offspring 
matched-controls.  
 
IGF-I system and glucose metabolism interactions in 
centenarians' offspring and offspring matched-controls 
As shown in Table 4, in the centenarians' offspring 
group circulating IGF-I bioactivity was positively 
related to total IGF-I (r=0.26, p=0.001) and negatively 
to HOMA2-S% (r=-0.18, p<0.05). Similarly, total IGF-I 
was inversely related to HOMA2-S% (r=-0.18, p<0.05). 
All these relationships remained significantly after 
correction for age, gender and BMI, except that between 
total IGF-I and HOMA2-S% resulting borderline 
significant (p=0.06). 
 
In offspring matched-controls (Table 4) circulating IGF-
I bioactivity was positively related to total IGF-I 
(r=0.32, p<0.05). Total IGF-I was also positively related 
to HOMA2-S% (r=0.24, p<0.05), but after correction 
for age, gender and BMI, this relationship became 
borderline significant (p=0.05). 
 
General characteristics and IGF/insulin system in 
centenarians 
 
The proportion of women was significantly higher in 
centenarians than in centenarians' offspring (Table 1).  
Table 2. Prevalence of some major age‐related diseases and medical therapy in offspring  
matched‐controls and centenarians' offspring 






    
Myocardial Infarction (%) 11 6 0.28 
Stroke (%) 6 2 0.22 
Hypertension (%) 63 37 <0.001 
Arrhythmia (%) 23 10 0.006 
Hypercholesterolemia (%) 47 40 0.18 
Diabetes (%) 10 10 0.99 
Dementia (%) 1.3 0.5 0.87 
Cancer (%) 20 11 0.06 
Osteoporosis (%) 26 19 0.18 
Osteoarthrosis (%) 56 44 0.06 
    
Medical Therapy     
Subjects taking drugs (%) 95 79 0.001 























































Height, BMI, systolic and diastolic blood pressures, 
total cholesterol levels, HDL levels and smoking 
prevalence were lower in centenarians compared to their 




















































Total IGF-I and IGFBP-3 values were significantly 
lower in centenarians compared to centenarians' 
offspring (both p<0.001, Table 3). While there were no 
significant differences in IGF-I bioactivity and IGF-
I/IGFBP-3 molar ratio between both groups. IGFBP-2 
Table 4. Correlation coefficients between parameters of the IGF‐I/insulin system in centenarians' 
offspring and in offspring matched‐controls         
  
 IGF-I Bioactivity 
 
Total IGF-I Total IGF-II HOMA2-B% 
     
Centenarians' offspring     
Total IGF-I 0.26b    
Total IGF-II 0.12 0.12   
HOMA2-B% 0.13 0.11 0.14  
HOMA2-S% -0.18a -0.18a -0.09 -0.48c 
     
Offspring matched-controls     
Total IGF-I 0.32a    
Total IGF-II 0.01 0.05   
HOMA2-B% -0.17 0.03 0.06  

















161 (134-187) 144 (119-170) 132 (107-157) <0.01 0.09 
Total IGF-I (nmol/L) 17 (13.6-20.8) 14.4 (11.9-18.2) 9.3 (7.1-12.9) <0.01 <0.001 
IGFBP-2 (μg/L) 546 (345-665) 566 (400-678) 728 (603-898) 0.50 <0.001 




79.8 (67.9-92.2) 0.01 <0.001 
Total IGF-I/IGFBP-3 
(molar ratio) 
0.15 (0.13-0.17) 0.12 (0.10-0.14) 0.13 (0.09-0.16) <0.001 0.42 
Total IGF-II (nmol/L) 114 (89-137) 134 (92-168) 72 (55-117) 0.15 <0.001 
Glucose (mmol/L) 4.9 (4.5-5.4) 4.8 (4.3-5.4) 4.6 (4.2-5.1) 0.38 0.09 
Insulin (pmol/L) 74 (51-105) 71 (44-103) 39 (27-70) 0.92 <0.001 
HOMA2-B% 128 (98-166) 137 (100-174) 109  (81-152) 0.94 <0.01 
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and total IGF-II were significantly higher and lower, 
respectively, in centenarians compared to centenarians' 
offspring (both p<0.001, Table 3). 
 
Insulin levels and HOMA2-B% were both significantly 
lower in centenarians than in the centenarians' offspring 
(p<0.001 and p<0.01, respectively, Table 3), while 
HOMA2-S% was significantly higher in centenarians 
than in centenarians' offspring (p<0.001, Table 3). 
 
In a subpopulation of 76 centenarian parents and their 
corresponding 76 offspring, IGF-I bioactivity levels 
showed a significant positive correlation between 
parent-offspring pairs (r=0.26, p=0.02, Figure 1). No 
significant associations were found for other 





























Although at first glance centenarians seem a good 
model to study determinants of longevity in humans, 
there are several limitations of using this approach: low 
prevalence (1 centenarian per 5-10.000 inhabitants), 
presence of frailty due to extreme age and lack of a 
control group of the same age [29, 30]. Due to these 
restrictions, centenarians are unsuitable to study age-
dependent variables (e.g. IGF-I) that may be involved in 
the modulation of the lifespan. In previous studies 
circulating IGF-I levels in long-lived people have been 
often compared to a control group of younger subjects 
[9, 10]. Therefore, in these studies it was not possible to 
conclude if IGF-I differences between both groups were 
expression of a different lifespan or of a physiological 
age-dependent IGF-I decline. 
 
Centenarians' offspring are more numerous than 
centenarians. Several epidemiological studies [31-33] 
have reported that centenarians' offspring have a 
survival advantage and a later onset for several diseases 
than age-matched controls. Offspring of long-lived 
siblings were shown to have a more beneficial 
metabolic profile and a better functional status 
compared to their controls [34, 35]. In addition, 
studying centenarians' offspring has the major 
advantage of the availability of an appropriate 
demographically-matched control group (subjects 
matched for age, sex, ethnicity, parent year of birth, 
born from non long-lived parents), thereby avoiding 
cohort effects. Therefore, this strategy seems a logic 
approach to identify potential factors involved in 
lifespan and healthy aging.  
 
To the best of our knowledge, this is the first study that 
evaluated circulating IGF-I bioactivity in centenarians' 
offspring. Circulating IGF-I bioactivity,  total IGF-I and  
total IGF-I/IGFBP-3 molar ratio were significantly 
lower in centenarians' offspring than in offspring 
matched-controls and these relationships remained after 
further adjustment for potential confounders. Both 
centenarians' offspring and controls were well-matched 
for age, gender, height, BMI, waist/hip ratio and 
smoking habits, while centenarians' offspring had a 
significant lower prevalence of some common age-
related diseases. In addition, a lower proportion of 
centenarians' offspring was treated with drugs. These 
findings suggest that: 1) the observed  differences in 
circulating IGF-I bioactivity, total IGF-I and IGF-
I/IGFBP-3 ratio, were not directly the consequence of 
differences in age or anthropometric parameters 
between centenarians' offspring and offspring matched-
controls; 2) centenarians' offspring were generally more 
healthy and predisposed to a longer survival than the 
control group. 
 
Growing evidence indicates a key role of the IGF-
I/IGF-IR system in regulating glucose metabolism by 
influencing β-cell function and insulin sensitivity [36]. 
IGF-I increases insulin sensitivity not only through its 
GH-suppressive effects but also by a direct activation of 
insulin receptor and IGF-IR [37-39]. In the present 
study, low IGF-I bioactivity in centenarians' offspring 
was inversely associated to insulin sensitivity, 
confirming previous data described in elderly [26] and 
Figure 1. Parent‐offspring correlation for IGF‐I bioactivity in a
subpopulation of 76 centenarians and  their corresponding 76
offspring.  No  such  correlation  was  observed  for  other  IGF‐
I/insulin system parameters. 
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healthy subjects [28]. This relationship remained after 
corrections for age, gender and BMI. In addition, 
centenarians showed a 2-fold higher insulin sensitivity 
and comparable glucose levels than their younger 
offspring, despite a lower circulating IGF-I bioactivity, 
which confirms previous studies reporting that 
centenarians have lower insulin levels but a better 
insulin action and glucose tolerance than relatively 
younger individuals [40, 41].   
 
Caloric restriction has been demonstrated to extend 
normal life span and improve health in many animal 
studies [1, 2, 42]. Animals show reduction in IGF-I and 
insulin levels as well as an increase in the sensitivity to 
insulin and IGF-I during limited caloric intake [1, 2, 
42]. Although only a few studies have really assessed 







































often suggested that many of the beneficial effects of 
caloric restriction are attained, at least in part, by down-
regulation of the IGF-I receptor/insulin receptor 
pathways. However, contrary to this widely held idea, it 
was recently found in an animal model that caloric 
restriction did not induce an uniform attenuation of 
IGF-I/insulin signalling [43]. The most surprising 
finding in this latter study was that caloric restriction 
induced stimulation of the post-receptor Akt pathway  
especially in skeletal muscles  [43]. An enhanced 
stimulation of Akt in skeletal muscles of caloric 
restricted animals is likely to be involved in an 
improved insulin-mediated glucose disposal. These 
results provide thus evidence that caloric restriction 
may improve insulin sensitivity due to a tissue-specific 
up-regulation of the post-receptor Akt pathway of the 








































Figure  2.  Hypothetical  relationships  between  caloric  restriction,  the  mTOR  pathway,  insulin  and  IGF‐I
receptor sensitivity, circulating  insulin  levels and  IGF‐I bioactivity. (A) Overnutrition results  in an  increased
activity  of  the  mTOR  pathway,  which  decreases  the  sensitivity  of  the  insulin  and  IGF‐I  receptors.  As  a
consequence there will be relatively high circulating insulin levels and IGF‐I bioactivity. (B) Caloric restriction
results  in a reduced activity of the mTOR pathway, which  increases the sensitivity of the  insulin and  IGF‐I
receptors. As a consequence there will be relatively low circulating insulin levels and IGF‐I bioactivity. 
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A target of rapamycin (mTOR)-centered model may 
further help to explain why the combination of 
relatively low IGF-I bioactivity and insulin levels with 
relatively high insulin responsiveness during caloric 
restriction is associated with good health and 
longevity. The mTOR pathway is involved in cellular 
senescence, aging and age-related diseases [44-46]. 
Normally the mTOR pathway is activated by 
numerous signals, including nutrients, IGF-I and 
insulin [44]. When the mTOR pathway is 
hyperactivated by overnutrition, it blocks the insulin 
action on glucose metabolism (Figure 2A). Insulin 
resistance results in elevated glucose levels and a 
compensatory insulin increase which will further 
deteriorate insulin sensitivity. Therefore it has been 
suggested that overnutrition induces insulin resistance, 
associated with accelerated aging and a shorter 
lifespan, through the hyper-activation of the mTOR 
pathway [44-46]. In contrast, caloric restriction 
deactivates the mTOR pathway (Figure 2B). This 
induces an improved insulin sensitivity and relatively 
low insulin levels and IGF-I bioactivity. Considering 
that insulin resistance plays a crucial role in 
determining several age-related diseases, it is 
reasonable to hypothesize that many of the anti-aging 
effects of caloric restriction are probably modulated by 
these pathways [44-46]. 
 
Interestingly, several IGF-I/insulin characteristics of the 
centenarians' offspring and centenarians in our study are 
comparable to those found in caloric restricted animals. 
Although cause and effect may be difficult to assess in a 
cross-sectional study, we hypothesize that, despite 
relatively low circulating IGF-I bioactivity, the insulin 
sensitizing effects of IGF-I at the post-receptor level 
were also up-regulated in centenarians' offspring and 
centenarians. 
 
In favour of our hypothesis, more than 15 years ago 
Parr [47] suggested that the ideal anti-aging setting for 
humans would be a high sensitivity to potentially 
dangerous hormones like IGF-I and insulin. He further 
suggested that increased IGF-IR and insulin receptor 
sensitivity, resulting in lower circulating IGF-I and 
insulin levels, might be the physiological basis for an 
improved balance of the insulin/IGF-I system. This 
strategy seems to permit a slower loss of physiologic 
reserve capacity and a longer lifespan.  
 
Unfortunately, in our study we were not able to measure 
individual IGF-IR sensitivity, insulin receptor 
sensitivity and post-receptor pathways of these two 
receptors to demonstrate that relatively low circulating 
IGF-I bioactivity in centenarians' offspring and 
centenarians is associated with higher IGF-I signalling 
pathway efficiency at the post-receptor level. 
 
A combination of genetic factors and lifestyle aspects 
seem to be transmitted to descendants of centenarians, 
who exhibit better risk profiles compared to age-
matched people without centenarians as parents [48]. 
Interestingly, we found that in contrast to circulating 
total IGF-I levels, mean IGF-I bioactivity was 
comparable between centenarians and their offspring. A 
potential role of the IGF-I system in the familial 
predisposition of centenarians' offspring to survive 
longer is further supported by the observation that only 
circulating IGF-I bioactivity was significantly 
correlated in parent-offspring pairs, showing a pattern 
of familial aggregation. Similarly, Bonafè et al. [9] 
reported previously that the relatively low levels of 
immunoreactive free IGF-I found in long-lived subjects 
were genetically determined and suggested an enhanced 
tissue response to IGF-I as consequence of an increased 
IGF-IR number/activity. 
 
In conclusion, we found that: 1) centenarians' offspring 
had relatively lower circulating IGF-I bioactivity, but 
still comparable insulin sensitivity and glucose 
tolerance than offspring matched-controls; 2) IGF-I 
bioactivity in centenarians' offspring was inversely 
associated to insulin sensitivity; 3) centenarians showed 
a 2-fold higher insulin sensitivity than centenarians' 
offspring. Our data support a role of the IGF-I/insulin 
system in the modulation of human aging process. We 
hypothesize that, despite low circulating IGF-I 
bioactivity, the post-receptor signalling pathways of the 
IGF-IR were up-regulated in centenarians' offspring and 





Demographic strategy for enrolment and model 
description. The subjects enrolled belonged to a large 
multicentric project entitled “Does parental longevity 
impact on the healthy ageing of their offspring?”. 
Within this framework, for the present study, we 
sampled 378 subjects living in Northern and Central 
Italy (Milan, Bologna and Florence): 106 centenarians 
(born between 1900-1908) and 192 centenarians' 
offspring. Seventy-six out of the 192 centenarians' 
offspring were actually offspring of the 106 included 
centenarians. In addition 80 offspring matched-controls 
(i.e. subjects age-matched to centenarians' offspring, but 
whose parents had died at a relatively young age) were 
included as controls. In this last group, parents were 
born in the same birth cohort of centenarians (1900-
1908), but they died by natural causes before reaching 
the average life expectancy calculated by the Italian 
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mortality tables (67 years for males and 72 years for 
females) (see website "Human Mortality Database" of 
the Max Plank Institute for Demography, Rostock, 
Germany: http://www.mortality.org/). The average life 
expectancy was calculated at 15 years of age. Such an 
approach takes into account the fact that the parents of 
the recruited subjects reached by definition the 
reproductive age. This allows to exclude potential 
biasing effects of infant mortality. 
 
Subjects were recruited through local advertisements 
and the Register Office. The participants’ ages were 
defined by birth certificates or dates of birth as stated on 
passports or identity cards. The exclusion criteria for the 
present study were: presence of cancer at the time of the 
interview, drugs (e.g. insulin, pharmacological doses of 
corticosteroids, selective estrogen receptor modulators, 
l-dopa, somatostatin analogues, etc.) and other factors 
that may actually have influenced IGF-I  levels.  
 
A full medical history was obtained from all subjects, 
followed by a physical examination and recording of 
systolic and diastolic blood pressure, height, weight, 
waist and hip circumferences for the assessment of BMI 
and waist to hip-ratio. A standard structured 
questionnaire was used to collect information about 
health status, currently used drugs, clinical history, and 
life style. This questionnaire was administered by 
trained staff (nurses and medical doctors). The history 
of past and current diseases was collected checking the 
participants' medical documentation and the current 
drug therapy. Venous blood samples were drawn 
between 7.30 and 9.00 a.m. under fasting conditions and 
immediately processed and remained frozen at -80°C 
until assayed.  
 
The study protocol was approved by the Ethical 
Committee of the Sant’Orsola-Malpighi University 
Hospital (Bologna, Italy) and from all participants 
written informed consent was obtained. 
 
Assays. IGF-I bioactivity was measured using an in-
house IGF-I KIRA assay, as previously described [24]. 
Human embryonic renal cells stably transfected with 
cDNA of the human IGF-IR gene were used as readout 
after stimulation with either recombinant IGF-I 
standards or 1/10 diluted serum samples at 37°C. IGF-I 
standards, two internal control samples, and serum 
samples from study participants were measured in 
duplicate on each culture plate. Intraassay and 
interassay CV were 6.0 and 10.9%, respectively. 
 
Total IGF-I was assayed by one-step sandwich 
chemiluminescence immunoassay (CLIA) after prior 
separation of IGF-I from binding proteins on the 
Liaison autoanalyzer (DiaSorin, Saluggia, Italy). 
Samples were acidified to separate IGF-I from binding 
proteins and excess IGF-II was used after acidification 
in order to avoid residual interference IGF-I with 
binding proteins. Intraassay and interassay CV were 4.4 
and 5.5%, respectively. The mean recovery value was 
97% of the hypothetical expected amount. 
 
IGF-II was measured by an Enzyme-Linked 
Immunosorbent Assay (ELISA), preceded by IGFBPs 
removal via acid-ethanol extraction, according to the 
manufacturer’s procedure (Diagnostic Systems 
Laboratories, Webster, Texas). Intraassay and interassay 
CV were 3.5 and 5.5%, respectively. The mean 
recovery value was 105% of the hypothetical expected 
amount. 
 
IGFBP-2 and IGFBP-3 were measured by ELISA 
according to the manufacturer’s procedure (Diagnostic 
Systems Laboratories, Beckman Coulter, Webster, 
Texas) in serum samples from 200 out of 378 
participants (70 centenarians, 85 centenarians' offspring 
and 45 offspring matched controls). Intraassay and 
interassay CV were 2.5% and 5.1% for IGFBP-2, 8.6% 
and 9.1% for IGFBP-3, respectively. IGFBP-3 was 
expressed as nmol/L in order to calculate IGF-I/IGFBP-
3 molar ratio, as a surrogate measure for IGF-I 
bioavailability. 
 
Serum insulin was measured by a CLIA on the fully 
automated platform Liaison (DiaSorin, Saluggia, Italy). 
Intraassay and interassay CV were 2.8 and 6%, 
respectively. Glucose, total cholesterol, HDL-
cholesterol and triglycerides were measured by standard 
laboratory procedures. Fasting indices of pancreatic β-
cell function (HOMA2-B%) and insulin sensitivity 
(HOMA2-S%) were calculated according to the 
homeostasis model assessment (HOMA) (HOMA 
Calculator version 2.2.2), available from 
http://www.dtu.ox.ac.uk [49]. 
 
Statistical analysis. The distribution of continuous 
variables was tested using the Shapiro-Wilk’s test. Data 
with normal distribution were reported as means and 
SD, whereas medians and interquartile ranges (25th-
75th percentiles) were used for data that did not meet 
the criteria for normality. For data that did not meet the 
criteria for normality, natural logarithmic 
transformations were applied. Comparison between 
groups was performed by using classical analysis of 
variance (ANOVA) and Kruskal Wallis test, 
respectively for parametric and nonparametric data. 
Bonferroni and Mann-Whitney test (corrected for 
multiple comparisons) were used as post-tests, 
respectively for parametric and nonparametric data. 
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Chi-square test was used to analyze categorical 
variables. Univariate general linear models were used to 
calculate age, gender and BMI-adjusted differences in 
the mean values of variables between groups. F test was 
used to calculate significance. Correlations between 
insulin/IGF-I system parameters were presented as 
Spearman correlation coefficients and partial correlation 
coefficients adjusted for potential confounding 
variables. All analyses were carried out using SPSS for 
Windows, release 17.0. A two-tailed p-value of < 0.05 




The authors would like to thank: 1) Dr. Andreasi 
Massimiliano and Dr. Marco Besozzi for their technical 
assistance in the IGF-I evaluation; 2) the Register 
Office of the City of Milan for its contribution in the 
collection of data; 3) the DiaSorin S.p.A., Saluggia 
(Vicenza), Italy for the measurement of insulin. This 
work has been partially supported by the Italian 
Ministry of University and Research (Project PRIN 
2009CB4C9F) and the European Union's Seventh 
Framework Programme (FP7/2007-2011, under grant 
agreement n. 223576). 
 
Conflict of Interest Statement 
 
The authors of this manuscript have no conflict of 










C,  Paolisso  G,  Monti  D.  Genes  involved  in  immune 
response/inflammation,  IGF1/insulin  pathway  and  response  to 
oxidative  stress  play  a  major  role  in  the  genetics  of  human 
longevity:  the  lesson of  centenarians. Mech Ageing Dev. 2005; 
126:351‐361. 
4.  Ugalde  AP,  Mariño  G,  López‐Otín  C.  Rejuvenating 
somatotropic  signaling:  a  therapeutical  opportunity  for 
premature aging? Aging (Albany NY). 2010; 2:1017‐1022. 
5.  Belfiore  A,  Frasca  F,  Pandini G,  Sciacca  L,  Vigneri  R.  Insulin 
receptor isoforms and insulin receptor/insulin‐like growth factor 
receptor  hybrids  in  physiology  and  disease.  Endocr  Rev.  2009; 
30:586‐623. 
6.  Van  Heemst  D,  Beekman  M,  Mooijaart  SP,  Heijmans  BT, 
Brandt BW, Zwaan BJ, Slagboom PE, Westendorp RG. Reduced 





results  from  a  healthy  Italian  population.  J  Endocrinol  Invest. 
2008; 31:445‐449. 
8. Kuk JL, Saunders TJ, Davidson LE, Ross R. Age‐related changes 
in  total  and  regional  fat  distribution.  Ageing  Res  Rev.  2009; 
8:339‐348.   
9.  Bonafe  M,  Barbieri  M,  Marchegiani  F,  Olivieri  F,  Ragno  E, 
Giampieri C, Mugianesi E, Centurelli M, Franceschi C, Paolisso G. 
Polymorphic  variants  of  insulin‐like  growth  factor  I  (IGF‐I) 
receptor  and  phosphoinositide    3‐kinase    genes    affect    IGF‐I  
plasma  levels  and  human longevity: cues for an evolutionarily 
conserved  mechanism  of  lifespan  control.  J  Clin  Endocrinol 
Metab. 2003; 88:3299–3304. 












13.  Rowlands  MA,  Gunnell  D,  Harris  R,  Vatten  LJ,  Holly  JM, 
Martin  RM.  Circulating  insulin‐like  growth  factor  peptides  and 
prostate cancer risk: a systematic review and meta‐analysis. Int J 
Cancer. 2009; 124:2416‐2429. 
14.  Major  JM,  Laughlin  GA,  Kritz‐Silverstein  D,  Wingard  DL, 
Barrett‐Connor  E.  Insulin‐Like  Growth  Factor‐I  and  Cancer 
Mortality in Older Men. J Clin Endocrinol Metab 2010; 95:1054–
1059. 
15.  Janssen  JA,  Lamberts  SW.  Igf‐I  and  longevity.  Horm  Res. 
2004; 62(Suppl 3):104‐109. 
16.  Janssen  JA,  Stolk  RP,  Pols  HA, Grobbee  DE,  Lamberts  SW. 
Serum  total  IGF‐I,  free  IGF‐I,  and  IGFBP‐1  levels  in  an  elderly 
population:  relation  to  cardiovascular  risk  factors  and  disease. 
Arterioscler Thromb Vasc Biol. 1998; 18:277–282. 
17.  Johnsen  SP,  Hundborg  HH,  Sørensen  HT,  Orskov  H, 
Tjønneland  A,  Overvad  K,  Jørgensen  JO.  Insulin‐like  growth 
factor (IGF)  I,  ‐II, and  IGF binding protein‐3 and risk of  ischemic 
stroke. J Clin Endocrinol Metab. 2005; 90:5937–5941. 
18. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T. Low 
serum  insulin‐like  growth  factor  I  is  associated with  increased 
risk of  ischemic heart disease: a population‐based  case‐control 
study. Circulation. 2002; 106:939–944. 
19.  Colao  A,  Di  Somma  C,  Cascella  T,    Pivonello  R,  Vitale  G, 
Grasso  L,  Lombardi  G,  Savastano  S.  Relationships  between 
serum  insulin‐like  growth  factor‐I  levels,  blood  pressure  and 
glucose  tolerance:  an  observational,  exploratory  study  in  404 
subjects. Eur J Endocrinol. 2008; 159:389‐397. 
20. Colao A, Di Somma C, Filippella MG, Rota F, Pivonello R, Orio 
F,  Vitale  G,  Lombardi  G.  Insulin‐like  growth  factor  deficiency 
determines  increased  intima‐media  thickness  at  common 
carotid  arteries  in  adult  patients  with  growth  hormone 
deficiency. Clin Endocrinol. 2004; 61:360‐366. 
21.  Galderisi  M,  Vitale  G,  Lupoli  G,  Barbieri  M,  Varricchio  G, 
Carella C, de Divitiis O, Paolisso G.  Inverse association between 
free  insulin‐like  growth  factor‐1  and  isovolumic  relaxation  in 
arterial systemic hypertension. Hypertension. 2001; 38:840‐845. 
  
www.impactaging.com                   588                                    AGING,  September 2012, Vol.4 No.9
22. Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale 
G,  de  Divitiis  O,  Paolisso  G.  Positive  association  between 
circulating free IGF‐1 levels and coronary flow reserve in arterial 
systemic hypertension. Am J Hypertens. 2002; 15:766‐772. 
23.  Rozing  MP,  Westendorp  RG,  Frölich  M,  de  Craen  AJ, 
Beekman M, Heijmans BT, Mooijaart SP, Blauw GJ, Slagboom PE, 




K,  Frystyk  J,  Lamberts  SW,  Janssen  JA.  Normal  values  of 
circulating  insulin‐like growth  factor‐I bioactivity  in  the healthy 
population:  comparison  with  five  widely  used  IGF‐I 
immunoassays. J Clin Endocrinol Metab. 2008; 93:2539‐2545. 
25. Brugts MP, van den Beld AW, Hofland LJ, van der Wansem K, 
van  Koetsveld  PM,  Frystyk  J,  Lamberts  SW,  Janssen  JA.  Low 







27. Chen  JW, Ledet T, Orskov H,  Jessen N, Lund S, Whittaker  J, 
De  Meyts  P,  Larsen  MB,  Christiansen  JS,  Frystyk  J.  A  highly 
sensitive and specific assay for determination of IGF‐I bioactivity 
in  human  serum.  Am  J  Physiol  Endocrinol  Metab.  2003; 
284:E1149‐E1155. 
28.  Arafat  AM,  Weickert  MO,  Frystyk  J,  Spranger  J,  Schöfl  C, 
Möhlig M, Pfeiffer AF. The role of insulin‐like growth factor (IGF) 







31.  Terry  DF,  Wilcox  MA,  McCormick  MA,  Pennington  JY, 
Schoenhofen  EA,  Andersen  SL,  Perls  TT.  Lower  all‐cause, 
cardiovascular, and cancer mortality in centenarians' offspring. J 
Am Geriatr Soc. 2004; 52:2074–2076. 
32.  Adams  ER,  Nolan  VG,  Andersen  SL,  Perls  TT,  Terry  DF. 
Centenarian  offspring:  Start  healthier  and  stay  healthier.  J Am 
Geriatr Soc. 2008; 56:2089–2092. 
33. Atzmon G, Schechter C, Greiner W, Davidson D, Rennert G, 
Barzilai N.  Clinical  Phenotype  of  Families with  Longevity.  J Am 
Geriatr Soc. 2004; 52:274‐277. 
34.  Mooijaart  SP,  van  Heemst  D,  Noordam  R,  Rozing  MP, 
Wijsman  CA,  de  Craen  AJ,  Westendorp  RG,  Beekman  M, 
Slagboom PE. Polymorphisms associated with type 2 diabetes in 
familial  longevity:  The  Leiden  Longevity  Study.  Aging  (Albany 
NY). 2011; 3:55‐62 
35. Newman AB, Glynn NW,  Taylor  CA,  Sebastiani  P,  Perls  TT, 
Mayeux R, Christensen K, Zmuda JM, Barral S, Lee JH, Simonsick 
EM,  Walston  JD,  Yashin  AI,  Hadley  E.  Health  and  function  of 
participants  in  the  Long  Life  Family  Study:  A  comparison with 
other cohorts. Aging (Albany NY). 2011; 3:63‐76. 




F,  Kiess  W.  An  insulin‐like  growth  factor‐I  receptor  defect 
associated  with  short  stature  and  impaired  carbohydrate 
homeostasis  in  an  Italian  pedigree.  Horm  Res  Paediatr.  2011; 
76:136‐143.  
38.  O’Connell  T,  Clemmons  DR.  IGF‐I/IGF‐binding  protein‐3 
combination  improves  insulin  resistance by GH‐dependent and 
independent  mechanisms.  J  Clin  Endocrinol  Metab.  2002; 
87:4356–4360. 
39. Rajpathak SN, Gunter MJ, Wylie‐Rosett J, Ho GY, Kaplan RC, 
Muzumdar  R,  Rohan  TE,  Strickler  HD.  The  role  of  insulin‐like 
growth  factor‐I and  its binding proteins  in glucose homeostasis 
and type 2 diabetes. Diabetes Metab Res Rev. 2009; 25:3‐12. 
40. Paolisso G, Gambardella A, Ammendola S, D'Amore A, Balbi 
V,  Varricchio  M,  D'Onofrio  F.  Glucose  tolerance  and  insulin 
action  in  healty  centenarians.  Am  J  Physiol.  1996;  270:E890‐
E894. 
41.  Barbieri M,  Rizzo MR, Manzella D,  Paolisso G.  Age‐related 
insulin  resistance:  is  it  an  obligatory  finding?  The  lesson  from 
healthy centenarians. Diabetes Metab Res Rev. 2001; 17:19‐26. 
42. D'Costa AP,  Lenham  JE,  Ingram RL, Sonntag WE. Moderate 
caloric  restriction  increases  type  1  IGF  receptors  and  protein 
synthesis in aging rats. Mech Ageing Dev. 1993; 71:59‐71. 
43.  Sharma  N,  Castorena  CM,  Cartee  GD.  Tissue‐Specific 
Responses  of  IGF‐1/Insulin  and  mTOR  Signaling  in  Calorie 
Restricted Rats. PLoS One. 2012; 7:e38835. 
44.  Blagosklonny  MV.  Calorie  restriction:  decelerating  mTOR‐
driven  aging  from  cells  to  organisms  (including  humans).  Cell 
Cycle. 2010; 9:683‐688. 
45.  Blagosklonny  MV.  Revisiting  the  antagonistic  pleiotropy 
theory  of  aging:  TOR‐driven  program  and  quasi‐program.  Cell 
Cycle. 2010; 9:3151‐3156. 
46. Blagosklonny MV. Once again on rapamycin‐induced  insulin 
resistance and  longevity: despite of or owing  to. Aging  (Albany 
NY). 2012; 4:350‐358. 
47.  Parr  T.  Insulin  exposure  controls  the  rate  of  mammalian 
aging. Mech Ageing Dev. 1996; 88:75‐82. 
48.  Galioto  A,  Dominguez  LJ,  Pineo  A,  Ferlisi  A,  Putignano  E, 





www.impactaging.com                    589                                 AGING, September 2012, Vol.4 No.9
